

FIG. 1








FIG. 2








- Natural Human TNF
- Recombinant Human TNF
- Control

FIG. 3









The first than that the second age of the second




FIG. 8A




FIG. 8B




FIG. 9A




FIG. 9B



 $y = 7.0802 - 5.9612 \times R^2 = 0.944$ ng Bound/(Free) $\times 10^8$ 4 I-125 murine A2 lgG Estimated Avg. Ka=0.5x109 0.2 0.6 0.0 0.8 0.4 ng Bound

FIG. 10A




FIG. 10B




FIG. 11




FIG. 12

Gl YPro IlePro Leu Asp Ser Asn Asn Pro Thr Ser Ala Ala lle Arg Ile His Lys Asn Leu Val Leu Thr Ile Glu Pro Leu Leu Leu Ile Gly Leu Tyr Ala Alà His Val Ala TyxGlu Leu Ile Ser Trp Ala Ala Leu Ile Asn Vál Glu Leu Ala His Pro Ser Lys Pro Val Gly Arg Asn Lys Leu Phe Ser Thr Ala Arg Arg Pro Ser Val Tyx10 Asp 130 Asp 110 Glu Asn 70 Pro Lys 50 Val 150 Val 30 Ser Leu Cys GlyG1nVal Thr Ala G1YPro Trp G1YGlyGln Leu Gln Glu Lys Thr Gln G1uGlnTyrSer Arg Leu Asn GlyProLeu Ser $_{
m G1u}$ Ser Gln Asp $\text{L}\gamma \text{s}$ Gln Thr Ala Val Ser Arg Glu Phe GlyAla Phe Leu Phe Ser Glu Leu Ile Arg Leu Asp Val Arg Glu Arg Ala Gly Val 141 Tyr 21 Gln 61 Gln Ser GlyCys Val 101 41

FIG. 13






FIG. 14A




FIG. 14B

Lys Pro Val Ala His Val Val Ala Asn The course were first order from the start first The first of the f Asp . Ser Arg Thr.Pro Ser Ser Arg Ser 1 Val

Pro G1yGlu Gly Gln Leu Gln Trp Leu Asn Arg Arg Ala Asn Ala Leu Léu Ala Asn 30 Ala Gln

Gly Leu Glu Ser Pro 50 Val Val Glu Leu Arg Asp Asn Gln Leu Val

Ser Ile Thr Tyr Leu Ile His Val Leu Leu Thr His Thr Ser Pro CysGlyGln GlyLys Phe Leu Val 61 G1n

Pro Ser Lys Ile Ile Glu Pro Ala 90 Lys Val Asn Leu Leu Ser TYTTrp 110 Glu Ala Lys Pro Thr Ala Gln GLYTyr Pro Glu Ser Thr Val Glu Ala Ile Arg Arg Gln Ser Cys 101

Leu

Tyr

Asp Pro. Ile Asn Arg Glu Ala Leu Ser Arg Asp 130 Phe Gln Leu Glu Lys Gly Val G1y121

Ile Ala Leu Tyr Phe Gly 1le 150 Val Gln G1ySer Glu Ala Phe .141 Tyr Leu Asp I

15 FIG.

Title: METHODS OF TREATING MYELODYSPLASTIC ..

Inventors: Junming Le, et al.

AspileLeuLeuThrGlnSerProAlaIleLeuSerValSerProGlyGluArgValSer GACATCTTGCTGACTCAGTCTCCAGCCATCCTGTCTGTGAGTCCAGGAGAAAGAGTCAGT

TTCTCCTGCAGGCCAGTCAGTTCGTTGGCTCAAGCATCCACTGGTATCAGCAAAGAACA PheserCysArgAlaSerGlnPheValGlySerSerIleHisTrpTyrGlnGlnArgThr AATGGTTCTCCAAGGCTTCTCATAAAGTATGCTTCTGAGTCTATGTCTGGGATCCCTTCC AsnGlySerProArgLeuLeuIleLysTyrAlaSerGluSerMetSerGlyIleProSer

ArgPheSerGlySerGlyThrAspPheThrLeuSerIleAsnThrValGluSer AGGTTTAGTGGCAGTGGATCAGGGACAGATTTTACTCTTAGCATCAACACTGTGGAGTCT

GAAGATATTGCAGATTATTACTGTCAAGAAAGTCATAGCTGGCCATTCACGTTCGGCTCG GluAspIleAlaAspTyrTyrCysGlnGlnSerHisSerTrpProPheThrPheGlySer

GGGACAAATTTGGAAGTAAAA GlyThrAsnLeuGluValLys 16A

Mer. 273 273 179 No. 273 No. 377 No. The think that the term the GAAGTGAAGCTTGAGGAGTCTGGAGGAGGCTTGGTGCAACCTGGAGGATCCATGAAACTC GluvalLysLeuGluGluSerGlyGlyGlyLeuvalGlnProGlyGlySerMetLysLeu

 ${\tt SerCysValAlaSerGlyPheIlePheSerAsnHisTrpMetAsnTrpValArgGlnSer}$ TCCTGTGTGCCTCTGGATTCATTTTCAGTAACCACTGGATGAACTGGGTCCGCCAGTCT

CCAGAGAAGGGGCTTGAGTGGGTTGCTGAAATTAGATCAAAATCTATTAATTCTGCAACA ProGluLysGlyLeuGluTrpValAlaGluIleArgSerLysSerIleAsnSerAlaThr

CATTATGCGGAGTCTGTGAAAGGGAGGTTCACCATCTCAAGAGATGATTCCAAAAGTGCT HisTyrAlaGluSerValLysGlyArgPheThrIleSerArgAspAspSerLysSerAla


GTGTACCTGCAAATGACCGACTTAAGAACTGAAGACACTGGCGTTTTATTACTGTTCCAGG ValTyrLeuGlnMetThrAspLeuArgThrGluAspThrGlyValTyrTyrCysSerArg


AATTACTACGGTAGTACCTACGACTACTGGGGCCAAGGCACCACTCTCACAGTGTCC AsnTyrTyrGlySerThrTyrAspTyrTrpGlyGlnGlyThrThrLeuThrValSer


Docket No.: 0975.1005-014


Title: METHODS OF TREATING MYELODYSPLASTIC ..


Inventors: Junming Le, et al.





















FIG. 23














Sal

Eco Xba

 amp^R

Klenow

re-ligate

-Xba


Klenow

Xba

Eco

Xba

FIG. 28






FIG. 30




FIG. 31A




FIG. 31B




FIG. 31C




FIG. 32






FIG. 33A









FIG. 33B

















*p \leq 0.05, **p \leq 0.01, *** p \leq 0.001 versus pre-infusion p \leq 0.05, ††p \leq 0.01, ††† p \leq 0.001 versus change in

FIG. 34